JO
ANTX icon

John Overdeck’s AN2 Therapeutics ANTX Stock Holding History

John Overdeck’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77K Buy
+15,913
New +$68.4K ﹤0.01% 4921
2026
Q1 		– Sell
-178,518
Closed -$204K – 4566
2025
Q4 		$204K Sell
178,518
-44,819
-20% -$52.3K ﹤0.01% 3757
2025
Q3 		$284K Sell
223,337
-15,010
-6% -$17.2K ﹤0.01% 3239
2025
Q2 		$253K Sell
238,347
-105,613
-31% -$126K ﹤0.01% 2847
2025
Q1 		$468K Sell
343,960
-56,372
-14% -$71K ﹤0.01% 2545
2024
Q4 		$552K Buy
400,332
+222,492
+125% +$270K ﹤0.01% 2490
2024
Q3 		$190K Buy
177,840
+45,752
+35% +$79.4K ﹤0.01% 2805
2024
Q2 		$284K Buy
132,088
+37,920
+40% +$90.3K ﹤0.01% 2619
2024
Q1 		$306K Buy
94,168
+74,920
+389% +$815K ﹤0.01% 2556
2023
Q4 		$394K Buy
+19,248
New +$322K ﹤0.01% 2573

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

John Overdeck's ANTX Position: Q2 2026 in Review

John Overdeck opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 15,913 shares worth $77K. The stake represents ﹤0.01% of the portfolio and ranks #4921 among its holdings. This is a return to the name: John Overdeck previously reported a position in ANTX as recently as Q4 2025.

John Overdeck first reported a position in ANTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $552K in Q4 2024. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • John Overdeck held 15,913 shares of AN2 Therapeutics worth $77K as of Q2 2026.
  • AN2 Therapeutics was a new John Overdeck position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4921 holding.
  • John Overdeck first reported a position in AN2 Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • John Overdeck's AN2 Therapeutics position peaked at $552K in Q4 2024.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.